2-((3,4-dimethoxyphenoxy)methyl)oxirane | 81528-38-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((3,4-dimethoxyphenoxy)methyl)oxirane
• 英文别名: 2-((3,4-dimethoxyphenoxy)methyl)ethylene oxide；3,4-Dimethoxyphenyl glycidyl ether；2-[(3,4-dimethoxyphenoxy)methyl]oxirane
• CAS: 81528-38-3
• 化学式: C₁₁H₁₄O₄
• 分子量: 210.23
• InChiKey: NXZRPCSZNMYJTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  40.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-((3,4-dimethoxyphenoxy)methyl)oxirane 在 硫氰酸铵 作用下， 以 水 为溶剂， 反应 0.17h， 以89%的产率得到2-(3,4-dimethoxyphenoxymethyl)thiirane
  参考文献：
  名称：

  在 EI-MS 中将环氧乙烷转化为硫杂丙环及其基峰的改进方法

  摘要：

  报道了一种将环氧乙烷转化为硫杂丙环的有效方法，该方法是在水介质中回流或微波照射下用过量的硫氰酸铵处理。

  DOI：

  10.3998/ark.5550190.0013.815
• 作为产物：
  描述：

  4-(allyloxy)-1,2-dimethoxybenzene 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-((3,4-dimethoxyphenoxy)methyl)oxirane
  参考文献：
  名称：

  在 EI-MS 中将环氧乙烷转化为硫杂丙环及其基峰的改进方法

  摘要：

  报道了一种将环氧乙烷转化为硫杂丙环的有效方法，该方法是在水介质中回流或微波照射下用过量的硫氰酸铵处理。

  DOI：

  10.3998/ark.5550190.0013.815

文献信息

• SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF
  申请人：CAO Bin

  公开号：US20100075994A1

  公开（公告）日：2010-03-25

  The present invention relates to a series of substituted dihydro and tetrahydro oxazolopyrimidinones, specifically, to a series of 2-substituted-2,3-dihydro-oxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetra-hydro-oxazolo[3,2-a]pyrimidin-7-ones of formula (I): Wherein p, n, X, Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein. This invention also relates to methods of making these compounds including novel intermediates. The compounds of this invention are modulators of metabotropic glutamate receptors (mGluR), particularly, mGluR2 receptor. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic neurodegenerative conditions, psychoses, convulsions, anxiety, depression, migraine, pain, sleep disorders and emesis.

  本发明涉及一系列取代二氢和四氢噁唑嘧啶酮，具体地说，涉及一系列式(I)的2-取代-2,3-二氢-噁唑并[3,2-a]嘧啶-7-酮和2-取代-2,3,5,6-四氢-噁唑并[3,2-a]嘧啶-7-酮： 其中p、n、X、Y、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。本发明还涉及制备这些化合物的方法，包括新颖的中间体。本发明的化合物是代谢型谷氨酸受体（mGluR）的调节剂，特别是mGluR2受体。因此，本发明的化合物在药物制剂中具有用途，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面，包括但不限于急性和慢性神经退行性疾病、精神病、癫痫、焦虑、抑郁、偏头痛、疼痛、睡眠障碍和呕吐。
• A facile and efficient method for synthesis of β-iodocarboxylates from terminal epoxides
  作者：Ye-Fu Zhu、Bo-Le Wei、Wen-Qiong Wang、Li-Jiang Xuan

  DOI：10.1016/j.tetlet.2019.151353

  日期：2019.12

  A facile and efficient method has been developed for synthesis of β-iodocarboxylates in the presences of Ph3P/I2. Starting from epoxides, a series of β-iodocarboxylate compounds can be directly obtained in toluene media with excellent yields. Moreover, the method was successfully applied for the late-stage modification of natural products, such as isosteviol and vincamine derivatives, achieving the

  已经开发了一种在Ph 3 P / I 2存在下合成β-碘代羧酸盐的简便有效的方法。从环氧化物开始，可以直接在甲苯介质中以优异的收率获得一系列β-碘代羧酸盐化合物。此外，该方法已成功地用于天然产物的后期修饰，例如异osteviol和长春胺衍生物，从而以良好的收率获得了相应的β-碘代羧酸盐。
• Syntheses of pterocarpenes and coumestans via regioselective cyclodehydration
  作者：Maloy Nayak、Youngeun Jung、Ikyon Kim

  DOI：10.1039/c6ob01451h

  日期：——

  pterocarpenes and coumestans is described. BCl3-mediated dehydrative cyclization of 1,3-diaryloxyacetones under mild conditions permitted regioselective ring closure to afford 3-((2-iodoaryloxy)methyl)benzofurans which were converted to the corresponding pterocarpenes by Pd-catalyzed intramolecular direct arylation. The subsequent benzylic oxidation led to coumestans. This sequence was applied to the formal

  描述了一种高效的合成方法，可合成萜烯和香豆素。在温和的条件下，BCl 3介导的1,3-二芳氧基丙酮的脱水环化使区域选择性闭环，得到3-（（2-碘芳氧基）甲基）苯并呋喃，其通过Pd催化的分子内直接芳基化反应转化为相应的茂木。随后的苄基氧化导致香豆素。该序列被应用于香豆酚的形式合成和拟合成的木瓜素结构，以及氟苯丙胺类化合物B和C的总合成。
• Cardioactive aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04438128A1

  公开（公告）日：1984-03-20

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamido, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, nitro, hydroxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-(lower alkoxycarbonyl)-ethyl, 2-carboxyethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.

  本发明提供了一般式为：##STR1##的芳氧基丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可能相同或不同，是氢或卤素原子或低碳基、氰基、羧酰胺基、羟基、低酰氧基、低烷氧基、低烯氧基或芳基低烷氧基基团，R.sub.5和R.sub.6，可能相同或不同，是氢原子或低碳基基团，X是直链或支链烷基链，含有2至6个碳原子，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个不是氢原子时，也可以是苯基基团，但是当A是尿嘧啶-6-基团时，尿嘧啶基团的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可能相同或不同，是来自氢、卤素、硝基、羟胺基、氨基、低酰胺基、低烷基氨基、二-(低烷基)-氨基、羟乙基氨基、二-(羟乙基)-氨基、羟基、低烷氧基、烯丙氧基、甲氧基低烷氧基、氰基、羧酰胺基、羧基、低烷氧基羧酰基、羟甲基、低烷氧甲基、卤甲基、氨基甲基、低酰氨基甲基、二-(低烷基)-氨基甲基、吡咯烷基甲基、哌啶基甲基、二-(羟乙基)-氨基甲基、吗啉基甲基、哌嗪基甲基、4-低酰基哌嗪基甲基、4-低烷基哌嗪基甲基、低烷基、低烯基、2-氰乙基、2-(低烷氧羰基)-乙基、2-羧乙基、2-羟乙基、苯基低烷基和苯基的单价或二价取代基，其中苯基基团可选地取代1或2个羟基或甲氧基，或来自氧或硫；其光学活性形式和其外消旋混合物，以及其药理兼容的盐。本发明还提供了制备这些化合物的方法和含有它们的制药组合物。
• Cardioactive pyrazole and imidazole aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04608383A1

  公开（公告）日：1986-08-26

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamide, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, notro, hydraxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, halomethyl, aminomethyl, lower acylaminomethyl, di(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acyaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them. These compounds are useful for the prophylaxis and combatting of cardiac and circulatory diseases.

  本发明提供了一般式为：##STR1## 的芳氧基丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可以相同或不同，是氢或卤素原子或低烷基、氰基、羧酰胺、羟基、低酰氧基、低烷氧基、低烯烃氧基或芳基低烷氧基基团，R.sub.5和R.sub.6，可以相同或不同，是氢原子或低烷基基团，X是含有2至6个碳原子的直链或支链烷基链，A是单环、双环或三环杂芳基或水杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个符号不是氢原子时，也可以是苯基基团，但前提是当A是尿嘧啶-6-基团时，尿嘧啶基团的5位不含有氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可以相同或不同，是从氢、卤素、硝基、羟基氨基、氨基、低酰胺基、低烷基氨基、二（低烷基）氨基、羟乙基氨基、二（羟乙基）氨基、羟基、低烷氧基、烯丙氧基、甲氧基低烷氧基、氰基、羧酰胺基、羧基、低烷氧羰基、羟甲基、低烷氧甲基、卤甲基、氨基甲基、低酰胺基甲基、卤甲基、氨基甲基、低酰胺基甲基、二（低烷基）氨基甲基、吡咯烷基甲基、吡啶烷基甲基、二（羟乙基）氨基甲基、羟基、低烷氧基、烯丙氧基、甲氧基低烷氧基、氰基、羧酰胺基、羧基、低烷氧羰基、羟甲基、低烷氧甲基、卤甲基、氨基甲基、低酰胺基甲基、二（低烷基）氨基甲基、吡咯啉基甲基、哌嗪基甲基、4-低酰基哌嗪基甲基、4-低烷基哌嗪基甲基、低烷基、低烯基、2-氰基乙基、2-羟基乙基、苯基低烷基和苯基的单价或二价取代基，其中苯基基团可以选择性地取代1或2个羟基或甲氧基基团，或者从氧或硫；其光学活性形式和混合物，以及其药理学上相容的盐。本发明还提供了制备这些化合物的方法和含有它们的制药组合物。这些化合物对于预防和治疗心脏和循环系统疾病是有用的。